Sofinno­va, For­bion back $70M push across fin­ish line for rare an­ti­fun­gal treat­ment

As the for­mer glob­al brand leader of Mer­ck’s an­ti­fun­gal busi­ness, Francesco Maria Lavi­no knows his facts: There are on­ly three class­es of an­ti­fun­gals.

But F2G, the biotech where he’s now CEO, is con­fi­dent that it can soon bring a fourth an­ti­fun­gal class to the mar­ket. And it’s closed $70 mil­lion in new fi­nanc­ing to get there.

The com­pa­ny has yet to un­veil da­ta from its open Phase IIb study in pa­tients with rare and re­sis­tant molds — it plans to do so at a con­fer­ence in Oc­to­ber — but the re­sults are ap­par­ent­ly pos­i­tive enough to ce­ment an FDA fil­ing by the end of the year. The agency has al­ready grant­ed its com­pound, named olo­rofim, des­ig­na­tions as a break­through ther­a­py, qual­i­fied in­fec­tious dis­ease prod­uct and or­phan drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER